On November 14, the 2026 Innovative Drug High-Quality Development Conference, jointly guided by the National Healthcare Security Administration and the Jiangsu Provincial People's Government, was held in Suzhou, with nearly 880 institutions and 1,500 industry representatives in attendance.
At the conference, the National Healthcare Security Administration released the "2026 Edition National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogue" and the "2026 Edition Commercial Health Insurance Innovative Drug Catalogue," and provided a detailed introduction to the catalogue adjustments.
The commercial health insurance catalogue is an institutional innovation in the development of China's multi-tiered medical security system. It is an important instrument for further clarifying the boundaries of basic medical insurance coverage and promoting the differentiated and complementary development of basic medical insurance and commercial health insurance. It focuses on including drugs with significant clinical value, a high degree of innovation, and clear patient benefits that fall beyond the scope of basic medical insurance coverage.
Specifically, in this round of adjustments to the commercial health insurance catalogue, 12 innovative drugs from 11 companies were newly included, bringing the total number of drugs in the commercial health insurance catalogue to 28. This further enriches the supply of products in frontier fields such as cell and gene therapy, rare diseases, and oncology.
In this round of adjustments to the basic medical insurance catalogue, a total of 107 drugs were newly added, and 34 varieties with no clinical supply or that can be better replaced were removed. After the adjustment, the total number of drugs in the catalogue increased to 3,331, including 1,935 Western medicines and 1,396 traditional Chinese patent medicines. The new edition of the catalogue will officially take effect on January 1, 2027.
Notably, products from Changtai Pharmaceutical, Healthgen Biotechnology, and Ascentage Pharma—three companies in which Efung Capital has invested—were successfully included as newly added varieties in the 2026 National Basic Medical Insurance Drug Catalogue. The inclusion of these three companies' innovative drug products in the national medical insurance catalogue marks authoritative recognition of their clinical value, innovation, and accessibility, and will further enhance patient access to the relevant innovative therapies, enabling more patients to access and afford high-quality innovative drugs.
With the implementation of the new edition of the basic medical insurance catalogue and the commercial health insurance innovative drug catalogue, the multi-tiered protection system for innovative drugs will become more complete, and the innovative drug industry is expected to embrace broader development space.
[Disclaimer]
The content of this article represents only the views of the Company based on currently available public information and materials provided by portfolio companies. It does not constitute any investment advice, medical advice, or guarantee of the performance of any specific company. Investment involves risks, and caution is advised when entering the market. Readers should make independent judgments based on public information. Unauthorized reproduction or use for commercial purposes is prohibited.